Patients can now receive long acting injectables to advance closing the gap in HIV prevention.
In a major step toward HIV prevention, CAN Community Health, the nation’s leading resource in ending epidemics, launched an innovative same-day injectable PrEP (Pre-Exposure Prophylaxis) model, revolutionizing access to HIV prevention by offering long-acting injectable medication on the same day of initiation consultation.
We are committed to eliminating health disparities and closing the gap in HIV prevention
said Rishi Patel, PharmD, MBA, President and CEO at CAN Community Health.
This innovative program significantly reduces the barriers to HIV prevention by streamlining the process from consultation to administration. With this new model, eligible patients can receive their first dose of injectable PrEP on the same day they walk into a CAN Clinic, enhancing both access and adherence in high-risk populations
said Marlon Pittman, Executive Vice President, Chief Operating Officer at CAN Community Health.
Injectable PrEP provides a discreet, long-acting alternative to daily pills and has proven especially beneficial for individuals who face challenges with daily medication adherence. CAN Community Health implemented the Test And Inject: Rapid Protect initiative to remove delays related to lab processing, insurance navigation, and pharmacy fulfillment—offering a patient-centered, equity-driven solution to HIV prevention.
We [CAN] are committed to eliminating health disparities and closing the gap in HIV prevention. By launching our same-day injectable PrEP model, we are accelerating our mission to end the HIV epidemic and empowering individuals to take immediate, proactive steps to protect their health
said Rishi Patel, PharmD, MBA, President and CEO at CAN Community Health.
The program is now available nationwide at CAN Community Health locations across Arizona, Florida, Nevada, South Carolina, Texas, and Virginia. Current patients can contact their clinic to make an appointment with their Provider. New patients can call (844) 922-2777 or chat with a representative online through the website.
For more information, read the original press release.
For more news from the world of long-acting therapeutics, sign up to the CELT's LONGEVITY mailing list here for regular updates.